What is HC Wainwright's Estimate for AGIO FY2025 Earnings?

Key Points

• HC Wainwright has revised its FY2025 earnings per share (EPS) estimate for Agios Pharmaceuticals to ($7.68), down from a previous estimate of ($7.62), while maintaining a "Buy" rating with a target price of $56.00.
• The company's last quarterly earnings report showed an EPS of ($1.93), which missed the consensus estimate of ($1.74) by ($0.19), despite outperforming revenue expectations.
• Insider sales have occurred, with CEO Brian Goff selling 11,085 shares recently, indicating potential shifts in ownership dynamics as insiders have sold a total of 57,448 shares over the last 90 days.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Stock analysts at HC Wainwright cut their FY2025 EPS estimates for Agios Pharmaceuticals in a report released on Thursday, September 4th. HC Wainwright analyst E. Bodnar now anticipates that the biopharmaceutical company will earn ($7.68) per share for the year, down from their previous estimate of ($7.62). HC Wainwright currently has a "Buy" rating and a $56.00 target price on the stock. The consensus estimate for Agios Pharmaceuticals' current full-year earnings is ($6.85) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals' Q4 2025 earnings at ($2.06) EPS and FY2029 earnings at ($6.50) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.19). Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. The company had revenue of $12.50 million for the quarter, compared to analyst estimates of $9.46 million.

Several other equities analysts have also weighed in on the stock. Scotiabank dropped their price objective on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating on the stock in a report on Monday, July 28th. Wall Street Zen lowered shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, May 19th. Finally, Bank of America lowered their target price on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $56.00.

Agios Pharmaceuticals Trading Down 0.3%

Shares of NASDAQ AGIO opened at $36.01 on Monday. The firm's 50-day moving average price is $37.58 and its 200-day moving average price is $33.20. Agios Pharmaceuticals has a 1-year low of $23.42 and a 1-year high of $62.58. The firm has a market capitalization of $2.09 billion, a P/E ratio of 3.27 and a beta of 0.87.

Insider Buying and Selling

In other Agios Pharmaceuticals news, CEO Brian Goff sold 11,085 shares of the company's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $36.67, for a total value of $406,486.95. Following the completion of the sale, the chief executive officer directly owned 123,528 shares of the company's stock, valued at approximately $4,529,771.76. This represents a 8.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director David Scadden sold 1,400 shares of the company's stock in a transaction dated Thursday, July 10th. The stock was sold at an average price of $40.00, for a total transaction of $56,000.00. Following the completion of the sale, the director directly owned 17,603 shares of the company's stock, valued at $704,120. The trade was a 7.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 57,448 shares of company stock worth $2,026,141 over the last ninety days. Insiders own 4.93% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Bellevue Group AG grew its position in shares of Agios Pharmaceuticals by 2.1% during the 2nd quarter. Bellevue Group AG now owns 3,590,150 shares of the biopharmaceutical company's stock valued at $119,408,000 after acquiring an additional 75,000 shares during the period. Commodore Capital LP grew its position in shares of Agios Pharmaceuticals by 6.4% during the 2nd quarter. Commodore Capital LP now owns 2,325,000 shares of the biopharmaceutical company's stock valued at $77,330,000 after acquiring an additional 140,000 shares during the period. Erste Asset Management GmbH grew its position in shares of Agios Pharmaceuticals by 10.9% during the 1st quarter. Erste Asset Management GmbH now owns 2,229,900 shares of the biopharmaceutical company's stock valued at $65,439,000 after acquiring an additional 220,000 shares during the period. Jefferies Financial Group Inc. bought a new position in shares of Agios Pharmaceuticals during the 4th quarter valued at approximately $49,290,000. Finally, Geode Capital Management LLC grew its position in shares of Agios Pharmaceuticals by 0.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,405,755 shares of the biopharmaceutical company's stock valued at $46,762,000 after acquiring an additional 11,174 shares during the period.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.